Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (111-120 of 181) with videos related to

Pageof 19
Sort By:
Cancer Immunology Research|September 19, 2019
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic LeukemiaPriyanka Banerjee, Ronghua Zhang, Cristina Ivan, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
Cancer|December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phaseKoji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
American Journal of Hematology|June 14, 2013
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemiaElias Jabbour, Koichi Takahashi, Xuemei Wang, et al.
Cancer|October 12, 2018
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemiaRita Assi, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Blood Neoplasia|January 15, 2026
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemiaTapan M Kadia, Akhil Jain, Caitlin R Rausch, et al.
Blood|October 16, 2004
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasStefan Faderl, Varsha Gandhi, Susan O'Brien, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Cancer Medicine|October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitorsAlejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Pageof 19

Showing results (111-120 of 181) with videos related to

Sort By:
Pageof 19
Cancer Immunology Research|September 19, 2019
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic LeukemiaPriyanka Banerjee, Ronghua Zhang, Cristina Ivan, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
Cancer|December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phaseKoji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
American Journal of Hematology|June 14, 2013
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemiaElias Jabbour, Koichi Takahashi, Xuemei Wang, et al.
Cancer|October 12, 2018
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemiaRita Assi, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Blood Neoplasia|January 15, 2026
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemiaTapan M Kadia, Akhil Jain, Caitlin R Rausch, et al.
Blood|October 16, 2004
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasStefan Faderl, Varsha Gandhi, Susan O'Brien, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Cancer Medicine|October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitorsAlejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Pageof 19